Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Medical Device

Sino Medical Secures Approval for Innovative Drug-Coated Stent System Targeting Intracranial Stenosis

Fineline Cube Apr 3, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), based in China, has announced that it has...

Company Drug

Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders

Fineline Cube Apr 3, 2024

China’s Junshi Biosciences (HKG: 1877; SHA: 688180) has announced the submission of two market approval...

Company

Takeda’s Strategic Shift: China Becomes Integral to Global R&D Pipeline

Fineline Cube Apr 3, 2024

Japan’s Takeda Pharmaceuticals (NYSE: TAK) has underscored its commitment to the Chinese market at this...

Company Drug

Zai Lab Announces Positive Phase III Data for Krazati in KRASG12C-mutated NSCLC, Plans NDA Filing in China

Fineline Cube Apr 2, 2024

Zai Lab (NASDAQ: ZLAB; HKG: 9688), a China-based biotech company, has announced positive Phase III...

Company Drug

Alexion’s Voydeya Earns FDA Nod as Add-on Therapy for PNH-Associated Extravascular Hemolysis

Fineline Cube Apr 2, 2024

Alexion, the rare disease unit of AstraZeneca (AZ; NASDAQ: AZN) based in the UK, has...

Company Drug

Viatris Launches Ryzumvi in the US for Rapid Reversal of Pharmacologically-Induced Pupil Dilation

Fineline Cube Apr 2, 2024

Viatris Inc. (NASDAQ: VTRS) has launched its alpha-adrenergic blocker Ryzumvi (phentolamine) in the US market,...

Company Medical Device

Huihe Healthcare’s Vispearl Microsphere Earns Marketing Approval in China for Innovative Cancer Treatment

Fineline Cube Apr 2, 2024

Shanghai-based Huihe Healthcare, a developer of interventional medical devices for structural heart diseases, has secured...

Company Drug

J&J’s Nipocalimab Fast-Tracked by FDA for Reducing FNAIT Risk in Pregnant Adults

Fineline Cube Apr 2, 2024

The US Food and Drug Administration (FDA) has accepted Johnson & Johnson’s (J&J; NYSE: JNJ)...

Company Policy / Regulatory

US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties

Fineline Cube Apr 2, 2024

Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to...

Company

Lepu Biotechnology Reports 1,347% YOY Revenue Increase in 2023 Financial Results

Fineline Cube Apr 2, 2024

Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has released its...

Company Deals

Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production

Fineline Cube Apr 2, 2024

Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen...

Company

Danaher Corporation Partners with Chongqing Liang Jiang New Area to Establish Western Innovation Center

Fineline Cube Apr 2, 2024

Danaher Corporation (NYSE: DHR), a leading science and technology services provider in the U.S., has...

Company Deals

China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases

Fineline Cube Apr 2, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement...

Company Drug

Shanghai Fosun Pharma and Meiji Seika Pharma Launch Phase III Studies for Anti-Infective Nacubactam

Fineline Cube Apr 2, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Medical Device

Johnson & Johnson MedTech Launches CPX4 PLUS Tissue Expander for Breast Reconstruction in China

Fineline Cube Apr 2, 2024

Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading healthcare conglomerate in the US, has...

Company Deals

ETERN Therapeutics Secures Funding to Advance LLPS Platform and Clinical Trials for Anti-Tumor Drugs

Fineline Cube Apr 2, 2024

ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced the commencement of a...

Company Drug

Junshi Biosciences Gets Green Light for Global Phase III Study of Tifcemalimab Combination Therapy in LS-SCLC

Fineline Cube Apr 2, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877), a leading biotech company based in China, has...

Policy / Regulatory

China’s National Joint Procurement Office Unveils Renewed Insulin Procurement Contracts

Fineline Cube Apr 1, 2024

The National Joint Procurement Office in China announced the upcoming renewal of drug procurement contracts...

Company Drug

FDA Reviews Eisai’s Monthly Maintenance Therapy for Early Alzheimer’s with Leqembi

Fineline Cube Apr 1, 2024

Last week, the US Food and Drug Administration (FDA) announced the acceptance of an indication...

Company Drug

Bristol Myers Squibb’s Krazati Trial Yields Positive Phase III Results in NSCLC

Fineline Cube Apr 1, 2024

Last week, Bristol Myers Squibb (BMS; NYSE: BMY) unveiled preliminary results from a Phase III...

Posts pagination

1 … 375 376 377 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.